story of the week
Mesenchymal Stem Cells vs Placebo in Multiple Sclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
Lancet Neurol 2021 Nov 01;20(11)917-929, A Uccelli, A Laroni, R Ali, MA Battaglia, M Blinkenberg, L Brundin, M Clanet, O Fernandez, J Marriot, P Muraro, SM Nabavi, RS Oliveri, E Radue, C Ramo Tello, I Schiavetti, J Sellner, PS Sorensen, MP Sormani, JT Wuerfel, MS FreedmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.